About DTx Pharma
DTx Pharma is a company based in San Diego (United States) founded in 2017 was acquired by Novartis in July 2023.. DTx Pharma has raised $13.2 million across 4 funding rounds from investors including Lilly, Novartis and NIH. DTx Pharma offers products and services including FALCON Platform and DTx-1252. DTx Pharma operates in a competitive market with competitors including Alnylam, Denali Therapeutics, Avidity Biosciences, Poseida Therapeutics and Castle Biosciences, among others.
- Headquarter San Diego, United States
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DTx Pharma
DTx Pharma offers a comprehensive portfolio of products and services, including FALCON Platform and DTx-1252. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables RNA delivery for genetic medicines beyond the liver.
Treats Charcot-Marie-Tooth Disease through RNA therapeutics.
Unlock access to complete
Unlock access to complete
Funding Insights of DTx Pharma
DTx Pharma has successfully raised a total of $13.2M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $2 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $2.0M
-
First Round
First Round
(25 Aug 2017)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Grant - DTx Pharma | Valuation |
investors |
|
| Jul, 2020 | Amount | Series A - DTx Pharma | Valuation |
investors |
|
| Sep, 2019 | Amount | Series A - DTx Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in DTx Pharma
DTx Pharma has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Novartis and NIH. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Angel Network for companies based in Southern California
|
Founded Year | Domain | Location | |
|
ExSight Ventures is focused on early-stage ophthalmic investments.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by DTx Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - DTx Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dtx Pharma Comparisons
Competitors of DTx Pharma
DTx Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Denali Therapeutics, Avidity Biosciences, Poseida Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dtx Pharma
Frequently Asked Questions about DTx Pharma
When was DTx Pharma founded?
DTx Pharma was founded in 2017.
Where is DTx Pharma located?
DTx Pharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is DTx Pharma a funded company?
DTx Pharma is a funded company, having raised a total of $13.2M across 4 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on Aug 25, 2017.
What does DTx Pharma do?
DTx Pharma was founded in 2017 in San Diego, United States, and operates in the biotechnology sector. RNA-based therapeutics are provided for personalized treatments across various therapeutic areas. A proprietary lipidation technology has been developed, enabling conjugation of long-chain fatty acids to siRNA for delivery to multiple cell types. Operations focus on advancing siRNA-based solutions in health applications.
Who are the top competitors of DTx Pharma?
DTx Pharma's top competitors include Juno Therapeutics, Alnylam and Avidity Biosciences.
What products or services does DTx Pharma offer?
DTx Pharma offers FALCON Platform and DTx-1252.
Who are DTx Pharma's investors?
DTx Pharma has 6 investors. Key investors include Lilly, Novartis, NIH, Viva Biotech, and Tech Coast Angels.